Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

Launched by NEXT BIOMEDICAL CO., LTD. · Apr 18, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called Nexpowder™ for people who experience diverticular bleeding in the lower part of the digestive system. Diverticular bleeding happens when small pouches in the intestines, called diverticula, become inflamed or bleed. The main goal of this study is to find out if Nexpowder™ is safe and effective in helping to manage this condition.

To join the trial, participants need to be adults aged 19 or older who have been diagnosed with diverticular bleeding. Unfortunately, those with bleeding in the upper gastrointestinal tract (which includes the stomach and upper intestines) cannot participate. The trial is not yet recruiting participants, so it's still in the planning stage. If someone is eligible and decides to participate, they will receive information about what to expect throughout the study, including any potential risks and benefits of using Nexpowder™. This trial is important because it could lead to better treatments for people suffering from diverticular bleeding.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 19 years or older at the time of screening
• • Patients diagnosed with diverticular bleeding
• Exclusion Criteria:
• • Patients diagnosed with upper gastrointestinal bleeding